The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism

Science

Volumn 279, Issue 5353, 1998, Pages 1054-1057

  Den Haan, Joke M M ^a   Meadows, Leslie M ^a   Wang, Wei ^a   Pool, Jos ^a   Blokland, Els ^a   Bishop, Tracie L ^a   Reinhardus, Carla ^a   Shabanowitz, Jeffrey ^a   Offringa, Rienk ^a   Hunt, Donald F ^a   Engelhard, Victor H ^a   Goulmy, Els ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLELE; ARTICLE; BONE MARROW TRANSPLANTATION; DNA POLYMORPHISM; DNA SEQUENCE; GRAFT VERSUS HOST REACTION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; AMINO ACID SEQUENCE; BONE MARROW TRANSPLANTATION; CELL LINE; CELL LINE, TRANSFORMED; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; MALE; MASS SPECTROMETRY; MINOR HISTOCOMPATIBILITY ANTIGENS; MINOR HISTOCOMPATIBILITY LOCI; OLIGOPEPTIDES; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 6844237658     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5353.1054     Document Type: Article

References (36)

1. P. G. Beatty et al., Transplantation 51, 443 (1991);
2. D. I. Marks et al., Ann. Intern. Med. 119, 207 (1993).
3. J. M. M. den Haan et al., Science 268, 1476 (1995).
4. W. Wang et al., ibid. 269, 1588 (1995).
5. L. Meadows et al., Immunity 6, 273 (1997).
6. E. Goulmy et al., N. Engl. J. Med. 334, 281 (1996).
7. C. A. van Els et al., Immunogenetics 35, 161 (1992).
8. M. de Bueger, A. Bakker, J. J. van Rood, F. Van der Woude, E. Goulmy, J. Immunol. 149, 1788 (1992); E. Van Lochem, M. van der Keur, A. M. Mommaas, G. C. de Gast, E. Goulmy, Transplant. Immunol. 4, 151 (1996); D. van der Harst et al., Blood 83, 1060 (1994).
9. M. de Bueger, A. Bakker, J. J. van Rood, F. Van der Woude, E. Goulmy, J. Immunol. 149, 1788 (1992); E. Van Lochem, M. van der Keur, A. M. Mommaas, G. C. de Gast, E. Goulmy, Transplant. Immunol. 4, 151 (1996); D. van der Harst et al., Blood 83, 1060 (1994).
10. M. de Bueger, A. Bakker, J. J. van Rood, F. Van der Woude, E. Goulmy, J. Immunol. 149, 1788 (1992); E. Van Lochem, M. van der Keur, A. M. Mommaas, G. C. de Gast, E. Goulmy, Transplant. Immunol. 4, 151 (1996); D. van der Harst et al., Blood 83, 1060 (1994).
11. G. M. Schreuder et al., Immunogenetics 38, 98 (1993).
12. + HLA-A*0201-restricted HA-1-specific CTL clones 3HA15, clone 15, and 5W38 were derived from PBMCs of two patients who had undergone HLA-identical BMT and were cultured as described [(6); E. Goulmy, J. W. Gratama, E. Blokland, F. E. Zwaan, J. J. van Rood, Nature 302, 159 (1983)].
13. 2O, pH 6.0] and buffer B [0.085% TEA in 60% acetonitrile, pH 6.0]. The gradient was 100% buffer A (0 to 5 min) and 0 to 100% buffer B (5 to 45 min) at a flow rate of 0.5 ml/min.
14. 9 equivalents, for 30 min at 37°C or 2 hours at room temperature. CTLs were added at effector:target ratios ranging from 9:1 to 33:1.
15. Fractions from third dimension HPLC separation of the Rp purification that contained HA-1 activity were analyzed by microcapillary HPLC-electrospray ionization mass spectrometry as described [(13); D. F. Hunt et al., Science 255, 1261 (1992)]. Mass spectra and CAD mass spectra were recorded on a Finnigan-MAT TSQ-7000 (San Jose, CA) triple quadrupole mass spectrometer equipped with an electrospray ion source.
16. A. L. Cox et al., Science 264, 716 (1994).
17. L. M. Meadows, W. Wang, T. L. Bishop, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, data not shown.
18. Single-letter abbreviations for the amino acid residues are as follows; A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; K, Lys; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; Y, Tyr; and X, either lle or Leu.
19. GenBank accession number D86976.
20. Total RNA or mRNA was prepared from BLCL with the RNAzol method (Cinaa/Biotecx Laboratories, Houston, TX) or according to manufacturer's instructions (QuickPrep mRNA Purification Kit, Pharmacia Biotech). cDNA was synthesized with 1 mg of RNA as template and with KIAA0223-based reverse primer 5′-GCT-CCT-GCA-TGA-CGC-TCT-GTC-TGCA-3′. To amplify the HA-1 region of KIAA0223 we used the following primers: forward primer 5′-GAC-GTC-GTC-GAG-GAC-ATC-TCC-CATC-3′ and reverse primer 5′-GAA-GGC-CAC-AGC-AAT-CGT-CTC-CAGG-3′. Cycle parameters used were as follows: denaturation at 95°C, 1 min; annealing at 58°C, 1 min; and extension at 72°C, 1 min (25 cycles). The PCR products were purified with the Magic PCR-Preps DMA purification system (Promega) and directly cloned with the pMosBiue T-vector kit (Amersham Life Science). Six independent colonies from each individual were sequenced with the T7 sequencing kit (Pharmacia Biotech).
21. J. Pool, J. M. M. den Haan, E. Goulmy, data not shown.
22. R allele primer R1, 5′-CCT-TGA-GAA-ACT-TAA-GGA-GTG-TGT-GTT-GCG-3′. For both reactions the reverse primer as described in (77) was used. Cycle parameters used were as follows: denaturation at 95°C, 1 min; annealing at 67°C, 1 min; and extension at 72°C, 1 min (25 cycles).
23. R BL cell line. Cycle parameters used were as follows: denaturation at 95°C, 1 mm; annealing at 60°C, 1 min; and extension at 72°C, 1 min (25 cycles). Purified DNA was directly cloned with the pMosBlue T-vector kit and recloned in the eukaryotic pCDNA3, 1(+) vector under the control of a cytomegalovirus (CMV) promoter. We performed transient cotransfections with HLA-A*0201 in HeLa cells using DEAE-Dextran coprecipitation. After 3 days of culture we added HA-1-specific T cells, and after 24 hours we measured the TNF-α release in the supernatant using WEHI cells [C. Traversari et al., Immunogenetics 35, 145 (1992)].
24. J. M. M. den Haan, E. Blokland, C. Reinhardus, E. Goulmy, data not shown.
25. T. L. Bishop, L. M. Meadows, W. Wang, J. Shabanowitz, D. F. Hunt, data not shown.
26. 50 was deduced for each peptide by using one-site competition nonlinear regression analysis with the GraphPad Prism software.
27. 50 was deduced for each peptide by using one-site competition nonlinear regression analysis with the GraphPad Prism software.
28. F. Ossendorp et al., Immunity 5, 115 (1996).
29. M. C. Morse et al., J. Immunol. 156, 3301 (1996); B. Loveland, C. R. Wang, H. Yonekawa, E. Hermel, K. F. Lindahl, Cell 60, 971 (1990); B. E. Loveland, K. Fischer Lindahl, in Antigen Processing and Recognition, J. McCluskey, Ed. (CRC Press, London, 1991), p. 173-192;
30. M. C. Morse et al., J. Immunol. 156, 3301 (1996); B. Loveland, C. R. Wang, H. Yonekawa, E. Hermel, K. F. Lindahl, Cell 60, 971 (1990); B. E. Loveland, K. Fischer Lindahl, in Antigen Processing and Recognition, J. McCluskey, Ed. (CRC Press, London, 1991), p. 173-192;
31. M. C. Morse et al., J. Immunol. 156, 3301 (1996); B. Loveland, C. R. Wang, H. Yonekawa, E. Hermel, K. F. Lindahl, Cell 60, 971 (1990); B. E. Loveland, K. Fischer Lindahl, in Antigen Processing and Recognition, J. McCluskey, Ed. (CRC Press, London, 1991), p. 173-192;
32. K. F. Lindahl, Trends Genet. 7, 219 (1991).
33. L. M. Mendoza et al., Immunity 7, 461 (1997).
34. P. J. Martin, Bone Marrow Transplant 8, 217 (1991).
35. N. Rufer et al., ibid. 19 (suppl. 1), S184 (1997).
36. We thank A. Geluk, M. Giphart, P. van den Elzen, and I. Schreuder for technical advice and scientific discussions, F. Koning and M. Oudshoorn for critical reading of the manuscript, and W. Benckhuisen and A. Naipal for the synthesis of peptides and oligonucleotides. Supported by grants from the Dutch Organization for Scientific Research (NWO 901-09-201 to J.d.H.), the J. A. Cohen Institute for Radiopathology and Radiation Protection (E.G.) and the U.S. Public Health Service (Al07496 to W.W., Al2T393 to V.H.E., and Al3393 to D.F.H.).